Therefore, a more detailed understanding of the PN components governing AAT-variant biogenesis and manipulating PN components by pharmacological intervention could potentially delay or even avoid the onset of AATD-related pathologies [4,11,12]. This evidence concerns the gene SERPINA1 and alpha 1-antitrypsin deficiency.